Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice.

We showed that Emicro-MiR-155 transgenic mice develop acute lymphoblastic leukemia/high-grade lymphoma. Most of these leukemias start at approximately 9 months irrespective of the mouse strain. They are preceded by a polyclonal pre-B-cell proliferation, have variable clinical presentation, are transplantable, and develop oligo/monoclonal expansion. In this study, we show that in these transgenic mice the B-cell precursors have the highest MiR-155 transgene expression and are at the origin of the leukemias. We determine that Src homology 2 domain-containing inositol-5-phosphatase (SHIP) and CCAAT enhancer-binding protein beta (C/EBPbeta), 2 important regulators of the interleukin-6 signaling pathway, are direct targets of MiR-155 and become gradually more down-regulated in the leukemic than in the preleukemic mice. We hypothesize that miR-155, by down-modulating Ship and C/EBPbeta, initiates a chain of events that leads to the accumulation of large pre-B cells and acute lymphoblastic leukemia/high-grade lymphoma.

[1]  Ryan M. O’Connell,et al.  Inositol phosphatase SHIP1 is a primary target of miR-155 , 2009, Proceedings of the National Academy of Sciences.

[2]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[3]  C. Hother,et al.  Onco-Mir-155 Targets SHIP to Regulate TNF-Dependent B-Cell Lymphoma Growth , 2008 .

[4]  Thomas D. Schmittgen,et al.  Analyzing real-time PCR data by the comparative CT method , 2008, Nature Protocols.

[5]  M. Lacey,et al.  MicroRNA-155 Is an Epstein-Barr Virus-Induced Gene That Modulates Epstein-Barr Virus-Regulated Gene Expression Pathways , 2008, Journal of Virology.

[6]  Aadel A. Chaudhuri,et al.  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.

[7]  Anton J. Enright,et al.  microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. , 2007, Immunity.

[8]  L. Lim,et al.  MicroRNA targeting specificity in mammals: determinants beyond seed pairing. , 2007, Molecular cell.

[9]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[10]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[11]  B. Calabretta,et al.  Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. , 2006, Blood.

[12]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[14]  A. van den Berg,et al.  BIC and miR‐155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas , 2005, The Journal of pathology.

[15]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[16]  S. Lowe,et al.  A microRNA polycistron as a potential human oncogene , 2005, Nature.

[17]  M. Caligiuri,et al.  Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation. , 2005, Blood.

[18]  Wayne Tam,et al.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[20]  C. Helgason,et al.  Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+/-SHIP-/- mice: a novel model of myelodysplasia. , 2004, Blood.

[21]  K. Coggeshall,et al.  Src Homology 2–containing 5-Inositol Phosphatase (SHIP) Suppresses an Early Stage of Lymphoid Cell Development through Elevated Interleukin-6 Production by Myeloid Cells in Bone Marrow , 2004, The Journal of experimental medicine.

[22]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Coggeshall,et al.  The Src homology 2 domain-containing inositol 5-phosphatase negatively regulates Fcgamma receptor-mediated phagocytosis through immunoreceptor tyrosine-based activation motif-bearing phagocytic receptors. , 2002, Blood.

[24]  G. Krystal,et al.  A Dual Role for Src Homology 2 Domain–Containing Inositol-5-Phosphatase (Ship) in Immunity , 2000, The Journal of experimental medicine.

[25]  J. Penninger,et al.  The Inositol Polyphosphate 5-Phosphatase Ship Is a Crucial Negative Regulator of B Cell Antigen Receptor Signaling , 1998, The Journal of experimental medicine.

[26]  P. Musiani,et al.  Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP beta-deficient mice , 1996, The Journal of experimental medicine.

[27]  R. Cortese,et al.  Lymphoproliferative disorder and imbalanced T‐helper response in C/EBP beta‐deficient mice. , 1995, The EMBO journal.

[28]  C. Trautwein,et al.  Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain , 1993, Nature.

[29]  S. Akira,et al.  Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Calame,et al.  The C/EBP family of transcriptional activators is functionally important for Ig VH promoter activity in vivo and in vitro. , 1992, Journal of immunology.

[31]  P. Rørth,et al.  A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. , 1992, Blood.

[32]  S. Akira,et al.  Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. , 1992, Blood.

[33]  A. Nienhuis,et al.  Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. , 1990, The Journal of clinical investigation.